ClinicalTrials.gg
CompletedNCT03466684BGFMUpdated Aug 31, 2018

BIA Guided-fluid Management in Postinjury Open Abdomen

An interventional study of BIA-guided fluid resuscitation protocol and Traditional fluid resuscitation protocol in Damage Control, Trauma Abdomen and Acute Compartment Syndrome, sponsored by Nanjing PLA General Hospital. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by Nanjing PLA General Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 2 months after the study started (first participant enrolled Jan 2013, registered Mar 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Fluid overload (FO), resulting from high volume fluid therapy, is frequent and contributes to excessive visceral edema, delayed fascial closure, and adverse outcomes among postinjury open abdomen (OA) patients. Bioelectrical impedance analysis (BIA) is a promising tool in monitoring fluid status and FO. Thus, we sought to investigate the efficacy of BIA-directed resuscitation among postinjury OA patients.

02

Conditions studied

  • Damage Control
  • Trauma Abdomen
  • Acute Compartment Syndrome

Keywords

  • Trauma
  • Open abdomen
  • Fluid resuscitation
  • Fascial closure
  • Bioelectrical impedance analysis
03

In context

Abdominal Injuries

60 studies on the registry are indexed under Abdominal Injuries; 19 are open to participants now.

This study's enrollment of 140 is above the median of 125 across 30 interventional studies indexed under Abdominal Injuries.

Browse Abdominal Injuries studies →

Lead sponsor

Nanjing PLA General Hospital is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult trauma patients admitted to SICU with OA after emergent abbreviated laparotomy were considered eligible.

Exclusion criteria

Exclusion Criteria:

  • (a) age less than 18 years; (b) pregnancy; (c) lactation; (d) limb amputations; (e) mental disorders; (f) diabetes mellitus; (g) pre-existing blood disorders; (h) pre-existing abdominal fistulas; (i) pre-existing terminal illness; (j) liver dysfunction ( class C); (k) (NYHA) class IV; (l) chronic renal failure requiring dialysis; (m) therapy with an extra-corporeal membrane oxygenator (ECMO); (n) enrolled in an ongoing, interventional RCT; (o) received prior fluids for resuscitation during their ICU stay; (p) expected to die within 1 hour of ICU admission for devastating injuries; (q) activated opt-out process for BGFM trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    BIA-directed fluid resuscitation

    After the achievement of CVP, MAP and ScvO2 goals, if hyperhydration (HL \> 74.3%) was found, then the following fluid management was applied with each passing 6h. If HL was above 87% (severe level), fluid infusion was restricted, a furosemide drip was used, and CRRT was initiated with an ultrafiltration rate when patients were failure or inadequate response to above diuretic therapy that gave a net negative fluid balance of at least 1500 ml during the next 6h. If HL was 81%-87% (moderate level), above methods were used to trigger a net negative fluid balance (about 1000 ml) for the next 6h. Similarly, If HL was 74.3%-81% (mild level), a net negative fluid balance of about 500 ml would be achieved during the next 6h of ICU hospitalization. If HL was blow 71%, a state of dehydration, CVP, MAP, and ScvO2 was maintained as above during ICU resuscitation.

    Other: BIA-guided fluid resuscitation protocol

  • Active comparator
    Traditional fluid resuscitation

    A timely restricted intravenous fluid regimen or dehydration therapy was implemented by two senior clinicians according to cumulative fluid balance recording and hemodynamic condition such as heart rate, blood pressure, central venous pressure, mean arterial pressure, urine output and body weight change.

    Other: Traditional fluid resuscitation protocol

Interventions

  • OtherBIA-guided fluid resuscitation protocol

    In both groups, a multi-frequency BIA with eight tactile electrodes (Inbody S10 Biospace, Biospace Co. Ltd., Seoul, Korea) was used to assess body fluid status every 6h within the first 72h after admission to the ICU and daily for a period of 4 days. BIA recording was not adjusted by clinicians in fluid restrict, pharmacological and mechanical means of therapy. In contrast, in group BIA, fluid resuscitation protocol with adjustment determined according to HL measured by BIA.

  • OtherTraditional fluid resuscitation protocol

    Traditional fluid resuscitation strategy determined by treating clinicians according to usual clinical parameters.

06

What researchers measure

Primary outcomes

  1. Rate of 30-day primary fascial closure

    Rate of 100% direct approximation of abdominal fascial edges

    Time frame: 30 days

Secondary outcomes

  1. Time to fascial closure

    Time to 100% direct approximation of abdominal fascial edges

    Time frame: 30 days

  2. Postoperative 7-day fluid volume

    Statistics of postoperative 7-day fluid volume Postoperative 7-day fluid fluid use during resuscitation

    Time frame: 7 days

  3. Postoperative 30-day mortality

    All cause mortality within 30 days

    Time frame: 30 days

  4. Postoperative 30-day adverse effects

    All cause adverse effects within 30 days

    Time frame: 30 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Dec 2017, 59 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2018
First posted
Mar 15, 2018
StartActual
Jan 1, 2013
Primary completionActual
Dec 31, 2017
CompletionActual
Mar 31, 2018
Last update
Aug 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03466684
Lead sponsor
Nanjing PLA General Hospital
Responsible party
Gao Tao (Clinical Professor, Nanjing PLA General Hospital) — Principal investigator
First posted
Mar 15, 2018
Start date
Jan 1, 2013
Primary completion
Dec 31, 2017
Completion
Mar 31, 2018
Last update
Aug 31, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion